文献速递淋巴瘤

低计数单克隆B细胞增多症COVID-19患者的免疫细胞动力学与抗体应答

Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.
PubMed 文献 · Am J Hematol · 2023-10-04

本研究对336例未接种SARS-CoV-2疫苗的COVID-19患者(74例MBLlo、262例非MBL)自感染起追踪43周,用高灵敏度流式细胞术分析免疫细胞动力学并同步ELISA测抗SARS-CoV-2抗体。MBLlo患者早期中性粒细胞、单核细胞及尤其浆细胞计数升高,而嗜酸性粒细胞、树突状细胞、嗜碱性粒细胞和淋巴细胞计数在可变比例样本中明显降低;与非MBL相比,MBLlo患者中性粒细胞更高、前生发中心B细胞、树突状细胞及先天样T细胞降低,浆细胞峰值延迟且第+2至+4周抗体水平更高。

要点

  • MBLlo COVID-19患者早期即出现中性粒细胞、单核细胞及浆细胞计数升高。
  • MBLlo患者嗜酸性粒细胞、树突状细胞、嗜碱性粒细胞及淋巴细胞计数降低,自第+5周起趋于正常。
  • 与非MBL相比,MBLlo患者浆细胞峰值延迟且第+2至+4周抗SARS-CoV-2抗体水平更高。

核心结论

  • MBLlo COVID-19患者具有既往在重型SARS-CoV-2感染中描述的免疫特征,并伴延迟但更显著的浆细胞与抗体体液应答。

研究设计与样本

  • 研究纳入336例未接种SARS-CoV-2疫苗的COVID-19患者,其中MBLlo 74例、非MBL 262例。
  • 自感染起追踪43周,采用高灵敏度流式细胞术分析血免疫细胞动力学,并行ELISA测血浆抗SARS-CoV-2抗体。

主要发现

  • 症状出现早期,MBLlo患者中性粒细胞、单核细胞及尤其浆细胞计数升高,嗜酸性粒细胞、树突状细胞、嗜碱性粒细胞和淋巴细胞计数在可变比例样本中明显降低。
  • 自感染第+5周起,上述降低的细胞计数趋于正常水平。
  • 与非MBL患者相比,MBLlo患者中性粒细胞计数更高,前生发中心B细胞、树突状细胞及先天样T细胞计数降低。
  • MBLlo患者浆细胞水平更高,伴浆细胞峰值延迟,且第+2至第+4周抗SARS-CoV-2特异性抗体血浆水平更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low-count monoclonal B-cell lymphocytosis (MBLlo ) has been associated with an underlying immunodeficiency and has recently emerged as a new risk factor for severe COVID-19. Here, we investigated the kinetics of immune cell and antibody responses in blood during COVID-19 of MBLlo versus non-MBL patients. For this study, we analyzed the kinetics of immune cells in blood of 336 COVID-19 patients (74 MBLlo and 262 non-MBL), who had not been vaccinated against SARS-CoV-2, over a period of 43 weeks since the onset of infection, using high-sensitivity flow cytometry. Plasma levels of anti-SARS-CoV-2 antibodies were measured in parallel by ELISA. Overall, early after the onset of symptoms, MBLlo COVID-19 patients showed increased neutrophil, monocyte, and particularly, plasma cell (PC) counts, whereas eosinophil, dendritic cell, basophil, and lymphocyte counts were markedly decreased in blood of a variable percentage of samples, and with a tendency toward normal levels from week +5 of infection onward. Compared with non-MBL patients, MBLlo COVID-19 patients presented higher neutrophil counts, together with decreased pre-GC B-cell, dendritic cell, and innate-like T-cell counts. Higher PC levels, together with a delayed PC peak and greater plasma levels of anti-SARS-CoV-2-specific antibodies (at week +2 to week +4) were also observed in MBLlo patients. In summary, MBLlo COVID-19 patients share immune profiles previously described for patients with severe SARS-CoV-2 infection, associated with a delayed but more pronounced PC and antibody humoral response once compared with non-MBL patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Oliva-Ariza G, Fuentes-Herrero B, Lecrevisse Q, et al. Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis. Am J Hematol. 2023. PMID: 37792579. doi:10.1002/ajh.27119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。